Humoral immune responses after receiving COVID-19 vaccination in cirrhotic patients.
- Conditions
- CirrhosisvaccinationCOVID-19cirrhosis, vaccination, COVID-19, CoronaVac, AstraZeneca, SARS-CoV-2 vaccine.
- Registration Number
- TCTR20210622002
- Lead Sponsor
- Faculty of Medicine, Prince of Songla University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. Age > 18 years old
2. Patients with the diagnosis of liver cirrhosis.
3. Plan to receive a COVID-19 vaccine.
Exclusion Criteria
1. Inability to provide informed consent.
2. Pregnancy
3. Receiving immunosuppressive drugs including prednisolone >15 mg/day
4. Immune deficiency including congenital or acquired immune deficiency
5. Known vaccine allergy
6. Not receiving a complete course of vaccination or receiving a different type of vaccine
7. Receiving other vaccines during COVID-19 vaccination
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method humoral response (SARS CoV-2 antibody level) after complete vaccination in cirrhotic patients Before compared with after vaccination Mean (SD), percentage
- Secondary Outcome Measures
Name Time Method Side effects after vaccination after vaccination percentage